Monday, May 23, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

by Medical Finance
in Coronavirus
Study: A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. Image Credit: Huen Structure Bio/Shutterstock
9
SHARES
103
VIEWS
Share on FacebookShare on Twitter

When coronavirus disease 2019 (COVID-19) first emerged, healthcare workers were frustrated by the lack of direct treatments for the disease. Without any medication that could directly target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, doctors were forced to treat the symptoms using supplemental oxygen and invasive mechanical ventilation. While monoclonal antibody treatments seemed promising, they suffered an early setback when the FDA canceled one of the first clinical trials due to a lack of evidence of efficacy. Now, researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.


Study: A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. Image Credit: Huen Structure Bio/ShutterstockStudy: A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. Image Credit: Huen Structure Bio/Shutterstock


A preprint version of the study is available on the bioRxiv* server while the article undergoes peer review.


The study


The researchers began by immunizing an alpaca with purified spike protein receptor-binding domain (RBD). After 50 days, the researchers harvested peripheral blood mononuclear cells (PBMCs), from which a VHH gene library was generated, and spike binding VHH genes were isolated by phage display.


Panning against purified full-length trimeric spike protein to maximize the native epitopes that match those present on the live virus. Following two rounds of panning, high-quality hits were identified by high-throughput ELISA of individual VHH clones on immobilized RBD. Any hits that showed significant binding ability were sequenced to determine the complementary-determining region 3 (CDR3) loops, and sequence families with significant enrichment were tested for neutralizing activity using lentivirus pseudotyped with the spike protein, with GFP as a reporter.


From these tests, one VHH clone, known as saRBD-1, completely neutralized the pseudovirus transduction and further testing revealed that the VHH was highly stable and could bind well to the native spike protein.


First, the researchers determined the subunit specificity of the VHH by ELISA on full-length trimeric spike protein, the S1, and S2 subunits, and the RBD. They found that saRBD-1 bound to the RBD strongest, with a 50% maximal binding response (EC50) of 607pM, followed by the S1 subunit at 200pM, the full-length protein at 100pM, and did not bind to the S2 subunit.


To compare the binding of saRBD-1 to the RBD with the binding of angiotensin-converting enzyme 2 (ACE2), the scientists performed biolayer interferometry, which showed a significant increase in binding of saRBD-1 compared to ACE2. To check if the nanobody could block the ACE2-RBD interaction, biolayer interferometry competition assays were performed, revealing a concentration of 6nM was sufficient to block 50% of ACE2 binding.


Following this, the scientists performed immunofluorescence microscopy on Vero E6 cells that were infected in the presence of either the control nanobody VHH52 or saRBD-1. They found that saRBD-1 completely blocked infection and followed this with virus neutralization assays, using both lentivirus pseudotyped with the SARS-CoV-2 spike protein and live SARS-CoV-2.


The saRBD-1 nanobody showed a 50% inhibition concentration (IC50) of 4.26nm, while the control nanobody showed no inhibition. Against the live virus, focus forming assays were performed that revealed the 50% focus neutralization titre at 5.82nm for Vero E6 cells. As expected, the control failed to prevent infection.


The researchers decided that as so many variants of concern carry significantly different spike proteins than the wild type, they should test saRBD-1s affinity for RBD carrying the mutation N501Y and its neutralizing abilities against isolates from variants of concern.


After generating a spike and RBD variant that contained N501Y, they used biolayer interferometry to show that the binding of saRBD-1 to the new variant was roughly equivalent to wild-type. For neutralization purposes, the researchers collected isolates from variants of concern with known mutations affecting the RBD. They performed neutralization assays, revealing that saRBD-1 shows improved neutralization again with most variants compared to wild-type.


Finally, the scientists wanted to discover the exact binding epitope of the nanobody, so they performed competitive binding assays against monoclonal antibodies. They tested against three primary classes of RBD binding antibodies, each of which targets epitopes in different locations. Class 1 antibodies tend to focus on epitopes with an up facing spike around K417, class 2 antibodies can bind both conformations and tended to be located around E484, and class 3 antibodies bind near L452. Their strongest results showed that saRBD-1 blocked the class 1 antibody B38 from binding, suggesting that saRBD-1 targets a similar site.


The conclusion


The authors have successfully identified, isolated, and tested a nanobody that shows significant ability to bind to the SARS-CoV-2 RBD and prevent infection. While further study and clinical trials are still needed, this could eventually become a potent medicine and help healthcare workers treat the more severe cases of COVID-19.


*Important notice


bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: SARS-CoV-2 Remains Infectious on Refrigerated Deli Food, Meats, and Fresh Produce for up to 21 Days. Image Credit: FamVeld/Shutterstock

How long does COVID-19 remain traceable on food?

by Medical Finance
May 23, 2022
0

When the coronavirus disease 2019 (COVID-19) first emerged, many governments issued advice to their citizens to help them avoid catching...

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Inmates who died asked for release before falling ill with covid

by Medical Finance
May 23, 2022
0

Rory Adams did not know that Christmas in a small rural hospital in West Virginia would be the last time...

Study: Impact of New Variants on SARS-CoV-2 Infectivity and Neutralization: A Molecular Assessment of the Alterations in the Spike-Host Protein Interactions. Image Credit: Kateryna Kon / Shutterstock

Research explains how SARS-CoV-2 variants evade some antibodies

by Medical Finance
May 23, 2022
0

A recent study published in the iScience Journal assessed the influence of new variants of severe acute respiratory syndrome coronavirus...

Study: Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19. Image Credit: bangoland/Shutterstock

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

by Medical Finance
May 23, 2022
0

Since coronavirus disease 2019 (COVID-19) first emerged in Wuhan, China, it has spread to nearly every country in the world...

Study: Multistate Outbreak of SARS-CoV-2 B.1.1.529 (Omicron) Variant Infections Among Persons in a Social Network Attending a Convention — New York City, November 18–December 20, 2021. Image Credit: Matej Kastelic/Shutterstock

Omicron outbreak in an indoor convention in New York

by Medical Finance
May 23, 2022
0

A recent report published by the Centers for Disease Control and Prevention (CDC), USA, has demonstrated one of the earliest...

Study: Consecutive deletions in a unique Uruguayan SARS-CoV-2 lineage evidence the genetic variability potential of accessory genes. Image Credit: Naeblys / Shutterstock.com

Research shows the impact of accessory genes deletion in SARS-CoV-2 evolution

by Medical Finance
May 23, 2022
0

In a recent study published in the journal PLoS ONE, researchers investigated the effect of genetic variability based on accessory...

Next Post
First patient-derived stem cell model developed for studying oculocutaneous albinism

New training scheme for convolutional neural networks automates cell segmentation and counting

Scientists identify a new switch for controlling motor proteins

Scientists discover how immune proteins defend plants against invading microorganisms

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Cardiopulmonary work up of patients with and without fatigue 6 months after COVID-19. Image Credit: Ann Kosolapova/Shutterstock
    Cardiopulmonary limitations six months after surviving COVID-19
  • Study: The changing impact of vaccines in the COVID-19 pandemic. Image Credit: Ramcreative / Shutterstock.com
    Impact of new COVID vaccinations as novel variants emerge
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply